162 related articles for article (PubMed ID: 21996729)
1. G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.
Cheriyath V; Kuhns MA; Jacobs BS; Evangelista P; Elson P; Downs-Kelly E; Tubbs R; Borden EC
Oncogene; 2012 Apr; 31(17):2222-36. PubMed ID: 21996729
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV
Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491
[TBL] [Abstract][Full Text] [Related]
3. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
4. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer.
Kenny FS; Willsher PC; Gee JM; Nicholson R; Pinder SE; Ellis IO; Robertson JF
Breast Cancer Res Treat; 2001 Jan; 65(2):135-44. PubMed ID: 11261829
[TBL] [Abstract][Full Text] [Related]
5. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
6. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.
Larsen MS; Bjerre K; Giobbie-Hurder A; Lænkholm AV; Henriksen KL; Ejlertsen B; Lykkesfeldt AE; Rasmussen BB
Acta Oncol; 2012 Jul; 51(6):781-9. PubMed ID: 22462654
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism.
Roberts CG; Gurisik E; Biden TJ; Sutherland RL; Butt AJ
Mol Cancer Ther; 2007 Oct; 6(10):2777-85. PubMed ID: 17913853
[TBL] [Abstract][Full Text] [Related]
11. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract][Full Text] [Related]
12. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
13. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
Wang S; Somisetty VS; Bai B; Chernukhin I; Niskanen H; Kaikkonen MU; Bellet M; Carroll JS; Hurtado A
Oncogene; 2020 Oct; 39(40):6300-6312. PubMed ID: 32843722
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
17. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
18. G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
Cheriyath V; Kaur J; Davenport A; Khalel A; Chowdhury N; Gaddipati L
Br J Cancer; 2018 Jul; 119(1):52-64. PubMed ID: 29899394
[TBL] [Abstract][Full Text] [Related]
19. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
20. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]